Thanks to private funding, 100% of every dollar donated to The Lustgarten Foundation goes directly to pancreatic cancer research.



17TH ANNUAL HOLIDAY ROCK & ROLL BASH RAISES MORE THAN $800,000 FOR
THE LUSTGARTEN FOUNDATION

All Money Raised Goes Directly to Pancreatic Cancer Research
Swizz Beatz and Radio City Rockettes Performed to Support the Fight Against Pancreatic Cancer
The Madison Square Garden Company and AMC Networks Hosted Event
at Tao Downtown in New York City


NEW YORK, NY, December 14, 2017 – On Wednesday evening, December 13, The Madison Square Garden Company (NYSE: MSG) and AMC Networks (NASDAQ: AMCX) hosted the 17th Annual Holiday Rock & Roll Bash to benefit the Lustgarten Foundation, the nation’s largest private funder of pancreatic cancer research. The Bash is the Foundation’s premier fundraising event, and this year, raised more than $800,000. Thanks to private funding, 100 percent of every dollar raised goes directly to pancreatic cancer research.

Entertainment for the event, held at Tao Downtown in New York City, included a special DJ set from Grammy Award winning music producer and recording artist Swizz Beatz, along with an exclusive performance from the Christmas Spectacular by the world-famous Radio City Rockettes.

“Over the past 17 years, the Bash has raised more than $23 million to further our goal of ending pancreatic cancer,” said Kerri Kaplan, president and chief executive officer of the Lustgarten Foundation. “The only way to achieve that goal is through research, and we have the most talented researchers diligently working on earlier detection methods and more effective treatments. We are incredibly grateful to MSG and AMC Networks for supporting us in this mission, and putting on this outstanding fundraising event.”

There has never been a more exciting time in pancreatic cancer research. Earlier this year, in an unprecedented, fast-tracked review, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) as the first immunotherapy treatment for advanced pancreatic cancer patients whose tumors are mismatch repair deficient. It is estimated that approximately 1 in 50 advanced pancreatic cancer patients have tumors that are mismatch repair deficient. The Lustgarten Foundation played a critical role in bringing Keytruda to pancreatic cancer patients by funding this innovative research, encouraging patients to get their tumors tested, and covering the cost of the test.

However, there is still much work to be done. Pancreatic cancer is swift and silent, and often undetected until it is too late. The overall five-year survival rate is still only eight percent and most with advanced pancreatic cancer die within a year. It is the third-leading cause of cancer deaths in the United States.

415 Crossways Park Drive, Suite D, Woodbury, NY 11797
Toll Free: 1-866-789-1000 P: 516-737-1550 F: 516-584-6265

logos-3-

2015 website development and design sponsored by Celgene